CBD Outperformed a Common Antipsychotic in Treating Autism-Like Behaviors in Zebrafish
In a zebrafish model of autism, CBD reversed hyperactivity and aggression more effectively than risperidone, while also addressing underlying neurobiological changes.
Quick Facts
What This Study Found
CBD treatment reversed VPA-induced hyperlocomotion and aggression in zebrafish, reduced lipid peroxidation, restored anandamide levels, and normalized markers of glial function. Risperidone showed limited behavioral improvement and did not affect these neurobiological markers.
Key Numbers
CBD at 0.06 microM reversed both hyperlocomotion and aggression. CBD reduced lipid peroxidation and restored anandamide levels. CBD normalized both GFAP and calcium/calmodulin expression.
How They Did This
Zebrafish embryos were exposed to sodium valproate (VPA) to induce autism-like features. At 3-4 days post-fertilization, embryos were treated with 0.06 microM CBD or 1 microM risperidone.
Why This Research Matters
Risperidone is one of only two FDA-approved medications for autism-related irritability, but it comes with significant side effects. This study suggests CBD may address not just behavioral symptoms but some of the underlying neurobiology.
The Bigger Picture
The endocannabinoid system plays an established role in neurodevelopment. This zebrafish study adds to preclinical evidence suggesting cannabinoids may have therapeutic potential in neurodevelopmental conditions.
What This Study Doesn't Tell Us
Zebrafish model cannot replicate full complexity of human autism. VPA-induced autism model represents only one possible pathway to ASD. Results cannot be directly translated to human dosing.
Questions This Raises
- ?Would these results hold in mammalian autism models?
- ?What dose of CBD in humans would correspond to the concentrations used here?
Trust & Context
- Key Stat:
- CBD normalized both glial markers and excitatory/inhibitory balance where risperidone did not
- Evidence Grade:
- Animal study in zebrafish; preclinical evidence that requires validation in mammalian models and human trials.
- Study Age:
- 2025 study with current preclinical methods
- Original Title:
- Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.
- Published In:
- Autism research : official journal of the International Society for Autism Research, 18(12), 2368-2381 (2025)
- Authors:
- Costa, Karla C M(2), Brigante, Tamires A V, Lirio, Pedro H C(2), Fernandes, Gabriel G, Scarante, Franciele F, Scomparin, Davi S, Ferreira, Rafael R, Vicente, Maria A, Abe, Flavia R, Guimarães, Francisco S, Hallak, Jaime E C, Crippa, Jose A, de Oliveira, Danielle P, Campos, Alline C
- Database ID:
- RTHC-06264
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does this mean CBD can treat autism in humans?
Not yet. This is a zebrafish study, which is very early-stage research. Extensive mammalian studies and human clinical trials would be needed.
Why did CBD work better than risperidone in this model?
CBD appeared to address multiple biological pathways: reducing oxidative stress, restoring endocannabinoid levels, and normalizing glial and signaling proteins. Risperidone primarily works on dopamine and serotonin receptors.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06264APA
Costa, Karla C M; Brigante, Tamires A V; Lirio, Pedro H C; Fernandes, Gabriel G; Scarante, Franciele F; Scomparin, Davi S; Ferreira, Rafael R; Vicente, Maria A; Abe, Flavia R; Guimarães, Francisco S; Hallak, Jaime E C; Crippa, Jose A; de Oliveira, Danielle P; Campos, Alline C. (2025). Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.. Autism research : official journal of the International Society for Autism Research, 18(12), 2368-2381. https://doi.org/10.1002/aur.70151
MLA
Costa, Karla C M, et al. "Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.." Autism research : official journal of the International Society for Autism Research, 2025. https://doi.org/10.1002/aur.70151
RethinkTHC
RethinkTHC Research Database. "Comparative Analysis of Cannabidiol and Risperidone on Behav..." RTHC-06264. Retrieved from https://rethinkthc.com/research/costa-2025-comparative-analysis-of-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.